Provectus Biopharmaceuticals, Inc.
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 2004-01-01
- Employees
- 4
- Market Cap
- -
- Website
- http://www.provectusbio.com
Clinical Trials
6
Trial Phases
2 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (5 trials with phase data)• Click on a phase to view related trials
A Phase 1 Study of PV-10 Chemoablation of Neuroendocrine Tumours (NET) Metastatic to the Liver
- Conditions
- Neuroendocrine Tumors Metastatic to the Liver
- Interventions
- First Posted Date
- 2016-02-26
- Last Posted Date
- 2023-02-08
- Lead Sponsor
- Provectus Biopharmaceuticals, Inc.
- Target Recruit Count
- 12
- Registration Number
- NCT02693067
- Locations
- 🇦🇺
The Queen Elizabeth Hospital, Woodville, South Australia, Australia
PV-10 in Combination With Pembrolizumab for Treatment of Metastatic Melanoma
- First Posted Date
- 2015-09-23
- Last Posted Date
- 2023-11-21
- Lead Sponsor
- Provectus Biopharmaceuticals, Inc.
- Target Recruit Count
- 50
- Registration Number
- NCT02557321
- Locations
- 🇺🇸
Moffitt Cancer Center, Tampa, Florida, United States
🇺🇸Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire, United States
🇺🇸Oregon Health & Science University, Portland, Oregon, United States
PV-10 vs Chemotherapy or Oncolytic Viral Therapy for Treatment of Locally Advanced Cutaneous Melanoma
- Conditions
- Cutaneous Melanoma
- Interventions
- Drug: PV-10 (10% rose bengal disodium)Drug: Dacarbazine, temozolomide or talimogene laherparepvec
- First Posted Date
- 2014-11-11
- Last Posted Date
- 2022-01-19
- Lead Sponsor
- Provectus Biopharmaceuticals, Inc.
- Target Recruit Count
- 20
- Registration Number
- NCT02288897
- Locations
- 🇺🇸
Sharp Memorial Hospital - Clinical Oncology Research, San Diego, California, United States
🇺🇸Mount Sinai Comprehensive Cancer Center, Miami Beach, Florida, United States
🇺🇸Moffitt Cancer Center and Research Institute, Tampa, Florida, United States
Expanded Access Protocol for PV-10 for Cutaneous or Subcutaneous Tumors
- Conditions
- Cutaneous or Subcutaneous Tumors Where There is no Comparable or SatisfactoryApproved Alternative Therapy
- First Posted Date
- 2010-12-15
- Last Posted Date
- 2016-07-11
- Lead Sponsor
- Provectus Biopharmaceuticals, Inc.
- Registration Number
- NCT01260779
- Locations
- 🇺🇸
University of Louisville, Louisville, Kentucky, United States
🇺🇸St Luke's University Health Network, Bethlehem, Pennsylvania, United States
🇺🇸MD Anderson Cancer Center, Houston, Texas, United States
A Study to Assess PV-10 Chemoablation of Cancer of the Liver
- Conditions
- Metastatic Ocular MelanomaMetastatic Uveal MelanomaHepatocellular CarcinomaMetastatic Lung CancerMetastatic Colon CancerCancer Metastatic to the LiverMetastatic MelanomaMetastatic Colorectal CancerMetastatic Pancreatic CancerMetastatic Breast Cancer
- Interventions
- Drug: PV-10 (10% rose bengal disodium)
- First Posted Date
- 2009-09-30
- Last Posted Date
- 2022-11-02
- Lead Sponsor
- Provectus Biopharmaceuticals, Inc.
- Target Recruit Count
- 78
- Registration Number
- NCT00986661
- Locations
- 🇺🇸
Sharp Memorial Hospital, San Diego, California, United States
🇺🇸Florida Hospital Tampa, Tampa, Florida, United States
🇺🇸St Luke's University Health Network, Bethlehem, Pennsylvania, United States